PHA/RMA News
Amgen's Dividend Track Record in Bear Markets Draws Defensive Demand as Fed Hike Cycle Pressures S&P 500
Amgen's bear market outperformance record draws defensive positioning demand as Fed hike cycle pressures equities
Sep 17, 2026
๐จ๐ฆ CanadaOptimi Health Launches Phase 3 MDMA Therapy Trial for PTSD โ 100 Veterans and Frontline Workers
Optimi Health (OPTH) launches Phase 3 trial of MDMA-assisted therapy for PTSD in up to 100 veterans and frontline workers
Sep 17, 2026
๐ฉ๐ช GermanyHandelsblatt Podcast Explores Whether German Tax Authority Accepts AirPods, Weight-Loss Injections, and Yoga Courses
A new ZEIT and Handelsblatt podcast examines which consumer purchases the German tax authority (Finanzamt) legally accepts as deductible
Sep 16, 2026
๐บ๐ธ United StatesBio-Techne Supplements Merger Proxy Amid Shareholder Lawsuit as Merck KGaA Vote Nears
Bio-Techne faces a merger lawsuit and voluntarily supplemented proxy disclosures including Goldman Sachs valuation analyses ahead of its shareholder vote on acquisition by Merck KGaA.
Sep 15, 2026
๐จ๐ฆ CanadaDefinium Therapeutics Reveals Phase 3 Anxiety Trial Results in Monday Webcast
Definium Therapeutics will host a live webcast Monday at 8am EDT to discuss topline results from its Phase 3 Panorama Study in Generalized Anxiety Disorder.
Sep 14, 2026
AXSMAxsome Therapeutics Shares Jump Nearly 6% as Auvelity Antidepressant Prescriptions Surge
Axsome Therapeutics (AXSM) shares rose nearly 6% in a single session following data showing a surge in prescriptions for Auvelity, the company's innovative antidepressant, signaling strong early commercial momentum for the drug.
Sep 12, 2026
๐บ๐ธ United StatesXORTX Therapeutics Surges 31% as Clinical and Commercial Manufacturing of XORLO Begins
XORTX Therapeutics (XRTX) shares surged 31% after announcing clinical and commercial manufacturing start for XORLO
Sep 12, 2026
IndiaNovartis India Surges 18% to Record High, Extends 9-Day Rally to 74% on Fresh Buying
Novartis India shares hit a record high on an 18% surge, extending a 74% gain in 9 trading days after fresh buying emerged following a new corporate development.
Sep 11, 2026
๐บ๐ธ United StatesAmgen's Imdelltra Posts 115% Sales Surge in Latest Quarterly Results
Amgen's cancer drug Imdelltra (tarlatamab) delivered a 115% year-over-year sales increase, becoming a key growth driver.
Sep 10, 2026
๐บ๐ธ United StatesTyra Biosciences Plunges 33% After Phase II Trial Misses Market Expectations
Tyra Biosciences (TYRA) shares fell 33% after Phase II clinical trial results failed to meet market expectations.
Sep 10, 2026
๐จ๐ณ ChinaHong Kong Targets Biomedicine Hub Status in Debut Five-Year Plan as GSK Signals Greater Bay Area Expansion
Hong Kong is set to place biomedicine at the centre of its first-ever five-year economic plan, while GSK reaffirms interest in Greater Bay Area biotech expansion at BIOHK conference.
Sep 10, 2026
๐ฏ๐ต JapanTSMC Records 53% Revenue Surge While Wegovy Advances in China, Validating AI and GLP-1 as Dual Growth Themes
TSMC's record August revenue surge of 53% and Wegovy's China market expansion confirm AI chips and GLP-1 obesity drugs remain the two dominant secular growth themes driving global equities.
Sep 10, 2026
๐ธ๐ฌ SingaporeEuropean Shares Turn Cautious as Oil Rally Fuels Inflation Fears, Novartis Tumbles
European equity markets turn muted as oil price rally fuels corporate margin and inflation concerns, while Novartis tumbles in company-specific decline adding to pharma sector pressure.
Sep 9, 2026
๐บ๐ธ United StatesNovartis Sinks 13.5% as Del-Desiran Fails Phase Trial, Putting $12B Avidity Deal Under Scrutiny
Novartis shares fell 13.5% after del-desiran, the lead drug in its $12 billion Avidity acquisition, missed its primary endpoint
Sep 9, 2026
๐บ๐ธ United StatesRoivant and Pharvaris Surge to Record Highs on Blowout Rare Disease Trial Results
Roivant Sciences and Pharvaris both hit record highs on clinical trial wins in lung disease and hereditary angioedema.
Sep 9, 2026
๐ GlobalInsilico Medicine's AI-Designed Lung Drug Reverses Aging Markers in Clinical Study Milestone
Insilico Medicine's AI-discovered lung drug demonstrated reversal of biological aging markers in a new clinical study
Sep 9, 2026
๐ฎ๐ณ IndiaBBB+/Baa1 Dual Ratings Secure Sun Pharma's Path to โน11.75B Organon Takeover
S&P assigned BBB+ and Moody's assigned Baa1 long-term ratings to Sun Pharma for the Organon acquisition
Sep 8, 2026
๐บ๐ธ United StatesMoody's Baa1, S&P BBB+ Ratings Pave Way for Sun Pharma's $11.75B Organon Acquisition
Moody's assigned Baa1 and S&P assigned BBB+ long-term ratings to Sun Pharma for its $11.75B Organon acquisition
Sep 8, 2026
๐ฎ๐ณ IndiaEuropean Equities Slip as Oil Surge Fans Inflation Fear; Novartis Plunges on Drug Trial Setback
The STOXX 600 fell 0.2% as surging oil prices rekindled European inflation concerns, while Novartis plunged after a second drug trial setback and Sandoz gained on long-term growth targets.
Sep 8, 2026
๐ฎ๐ณ IndiaSai Life Sciences Hits Fresh Record High With 84% Gain in 2026 as Pharma Momentum Builds
Sai Life Sciences shares gain 5% to a new all-time high, leading the Nifty Pharma index in 2026
Sep 8, 2026
๐ฎ๐ณ IndiaMounjaro Sales Up 502% as GLP-1 Drugs Reshape India's Pharma Landscape
Mounjaro became India's top-selling pharma brand with โน1,256 crore in MAT sales, a 502% surge year-over-year per PharmaTrac August 2026 data
Sep 8, 2026
๐บ๐ธ United StatesEli Lilly's Acquisition Spree and GLP-1 Leadership Set the Stage for Long-Term Growth
Eli Lilly has been acquiring companies at an accelerated pace, building a pipeline beyond its GLP-1 franchise.
Sep 8, 2026
๐บ๐ธ United StatesEuropean Markets Slip on Oil Price Surge and Novartis Stock Decline
European equity markets dipped as a concurrent oil price surge and Novartis stock decline weighed on indices.
Sep 8, 2026
๐ฎ๐ณ IndiaSai Life Sciences Near All-Time High: 90%+ Repeat Revenue and CDMO Integration Signal New Growth Phase
Sai Life Sciences is operating near all-time high stock price with over 90% of revenue from repeat customers.
Sep 8, 2026
๐ฎ๐ณ IndiaRPG Life Sciences Targets Bigger API Expansion After โน215 Crore Acquisitions; GLP-1 Launch in October
RPG Life Sciences spent โน215 crore acquiring Actis Generics and Raghava Life Sciences in five weeks, boosting API capacity fivefold to 505 KL.
Sep 8, 2026
๐ง๐ท BrazilFDA Authorizes 11 Philip Morris Zyn Products, Bolstering Nicotine Pouch Market Position
Philip Morris International received FDA marketing authorization for 11 Zyn nicotine-pouch products in the US.
Sep 8, 2026
๐จ๐ฆ CanadaTeva Pharmaceutical Launches EUR and USD Senior Notes Offering Via Dutch Finance Subsidiaries
Teva Pharmaceutical announced plans to issue EUR-denominated and USD-denominated senior notes through its Dutch finance subsidiaries.
Sep 8, 2026
๐ฐ๐ท South KoreaHanmi Pharma Pairs Obesity Drug 'Efe' With Digital Health App to Improve Long-Term Outcomes
Hanmi Pharmaceutical is combining its obesity drug 'Efe' with a smartphone app for integrated patient monitoring
Sep 6, 2026
๐ฆ๐บ AustraliaWiseTech Global (WTC) and CSL Ltd (CSL): Two ASX Shares to Watch on Valuation and Strategic Momentum
WiseTech Global and CSL emerge as two high-conviction ASX watches, with WTC's CargoWise platform benefiting from freight digitisation and CSL's plasma expansion supporting long-duration biotech growth.
Sep 6, 2026
๐ฎ๐ณ IndiaNovartis India Eyes Therapy-Aligned Acquisitions Across Five Health Sectors, Targets Tier 2-3 Market Expansion
Novartis India targets therapy-aligned acquisitions across pain, wellness, women's health, neuroscience, and transplant immunology while expanding into Tier 2-3 markets.
Sep 6, 2026